JP2012511895A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511895A5
JP2012511895A5 JP2011536563A JP2011536563A JP2012511895A5 JP 2012511895 A5 JP2012511895 A5 JP 2012511895A5 JP 2011536563 A JP2011536563 A JP 2011536563A JP 2011536563 A JP2011536563 A JP 2011536563A JP 2012511895 A5 JP2012511895 A5 JP 2012511895A5
Authority
JP
Japan
Prior art keywords
patent document
diseases
brain
neurological
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536563A
Other languages
English (en)
Other versions
JP2012511895A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/064617 external-priority patent/WO2010057112A2/en
Publication of JP2012511895A publication Critical patent/JP2012511895A/ja
Publication of JP2012511895A5 publication Critical patent/JP2012511895A5/ja
Pending legal-status Critical Current

Links

Description

【0005】
神経疾患は、脳、脊髄、及び神経の疾患に起因することがある。神経疾患患者は、行動、言語、嚥下、呼吸または学習トラブルを有することがある。記憶障害、行動または心的認識の問題もまた、神経疾患に関連している。神経機能障害には様々な根本的な原因がある。これらには、遺伝的変異、有害物質への曝露及び障害を含めることができる。
神経疾患は600種以上存在する。主なタイプは、ハンチントン病及び筋ジストロフィーのような遺伝子欠損により引き起こされる疾患;二分脊椎のような神経系の異常胚発達;パーキンソン病及びアルツハイマー病のような神経細胞が損傷または死んでいる変性疾患、脳卒中のような脳に血液を供給する血管の疾患;脊髄及び脳への傷害;癲癇のような発作障害;脳腫瘍のような癌;髄膜炎のような感染症を含む。
ヒトの認知及び行動の複数の疾患は、遺伝的要因により変調するように思われる。しかしながら、遺伝的変異の影響する疾患の様式は複雑であり、よくわかっていない。同様にとらえどころのないことして、診断及び治療介入に関して有用な特定の遺伝子の正体が挙げられる。本発明の目的はこれらの遺伝子マーカーを提供すること及びさらには認知機能及び神経発達の損失につながる変化を特徴づけることである。
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
【先行技術文献】
【特許文献】
【0006】
【特許文献1】 米国特許出願公開第2005/10209181号明細書
【特許文献2】 米国特許出願公開第2006/0051786号明細書
【非特許文献】
【0007】
【非特許文献1】 SEO et al. An accurate method for quantifying and analyzing copy number variation in porcine KIT by an oligonucleotide ligation assay. BMC Genet. 2007, 8(Artlcle 81):1−11; Abstract.
【非特許文献2】 MARSHALL et al. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. February 2008, 82(2):477−488.
【非特許文献3】 KUOKKANEN et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am. J. Hum. Genet. December 1997, 61(6):1379−1387.
【非特許文献4】 CHARDENOT et al. Expression profile and up−regUlation of PRAX−1 mRNA by antidepressant treatment in the rat brain. Mol. Pharmacol. 2002, 62(6):1314−1320.
【非特許文献5】 GALLIEGUE et al. Cloning and characterization of PRAX−1. A new protein that specifically interacts with the peripheral benzodlazepine receptor. J. Bioi. Chem. 1999,274(5):2938−2952.
【非特許文献6】 BUCAN et al. Genome−wide analyses of exonlc copy number variants In a family−based study point to novel autism susceptibility genes. PLoS Genet. June 2009, 5(6):article e1000536, pages 1−12.
【発明の概要】
【課題を解決するための手段】
JP2011536563A 2008-11-14 2009-11-16 ヒト認知の原因となる遺伝子変異体及び診断標的及び治療標的としてのそれらを使用する方法 Pending JP2012511895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11492108P 2008-11-14 2008-11-14
US61/114,921 2008-11-14
PCT/US2009/064617 WO2010057112A2 (en) 2008-11-14 2009-11-16 Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets

Publications (2)

Publication Number Publication Date
JP2012511895A JP2012511895A (ja) 2012-05-31
JP2012511895A5 true JP2012511895A5 (ja) 2013-01-17

Family

ID=42170776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536563A Pending JP2012511895A (ja) 2008-11-14 2009-11-16 ヒト認知の原因となる遺伝子変異体及び診断標的及び治療標的としてのそれらを使用する方法

Country Status (6)

Country Link
US (3) US20110311512A1 (ja)
EP (1) EP2376655B1 (ja)
JP (1) JP2012511895A (ja)
AU (1) AU2009313759B2 (ja)
CA (1) CA2766246C (ja)
WO (1) WO2010057112A2 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
JP5881420B2 (ja) * 2008-11-12 2016-03-09 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 自閉症関連遺伝子マーカー
JP5728813B2 (ja) * 2010-02-25 2015-06-03 国立大学法人三重大学 冠動脈疾患の遺伝的リスク検出法
US8862410B2 (en) 2010-08-02 2014-10-14 Population Diagnostics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
AU2011293363A1 (en) * 2010-08-24 2013-02-28 The Children's Hospital Of Philadelphia Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (ADHD) and methods of use thereof for the diagnosis and treatment of the same
WO2013006857A1 (en) * 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2016022324A1 (en) * 2014-05-30 2016-02-11 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
CA2863887C (en) 2012-02-09 2023-01-03 Population Diagnostics, Inc. Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
US9714450B2 (en) 2012-08-31 2017-07-25 New York University Methods for diagnosing and treating schizophrenia
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
EP2900835A4 (en) 2012-09-27 2016-05-11 Population Diagnotics Inc METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS
EP2904117A4 (en) * 2012-10-04 2016-11-09 Lineagen Inc ASSOCIATED GENETIC MARKERS ASSOCIATED WITH ASD AND OTHER CHILDHOOD DEVELOPMENT DISORDERS
WO2014121180A1 (en) * 2013-02-01 2014-08-07 The University Of Chicago Genetic variants in interstitial lung disease subjects
WO2014152965A2 (en) * 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
JP6104058B2 (ja) * 2013-06-03 2017-03-29 花王株式会社 カビ臭抑制剤の探索方法
US11219617B2 (en) 2014-05-30 2022-01-11 The Children's Hospital Of Philadelphia Methods of diagnosing and treating autism
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
EP3347016B1 (en) 2015-09-08 2021-04-28 The Children's Hospital of Philadelphia Diagnosing and treating anxiety disorder
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
JP6942036B2 (ja) * 2017-11-30 2021-09-29 藤倉化成株式会社 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー
CA3108807A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
KR102250063B1 (ko) * 2019-06-14 2021-05-12 한국생명공학연구원 뚜렛증후군의 원인 유전자를 동정하는 방법
KR102189144B1 (ko) * 2020-10-15 2020-12-09 서울대학교병원 만성신장질환 악화 예측 마커 및 이를 이용한 악화 예측 방법
US20220403469A1 (en) * 2021-06-17 2022-12-22 United States Government As Represented By The Department Of Veterans Affairs Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
EP1766077B1 (en) * 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder

Similar Documents

Publication Publication Date Title
JP2012511895A5 (ja)
Lee et al. De novo mutations in the motor domain of KIF1A cause cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy
Urano Wolfram syndrome: diagnosis, management, and treatment
Züchner et al. Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies
Valdmanis et al. Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p
Workman et al. Rapid antidepressants stimulate the decoupling of GABAB receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3η
Field et al. Expanding the molecular basis and phenotypic spectrum of X-linked Joubert syndrome associated with OFD1 mutations
Darvesh et al. Reduced fibrillar β-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model
Hirst et al. Complicated spastic paraplegia in patients with AP5Z1 mutations (SPG48)
JP7105256B2 (ja) 伸長ヌクレオチド反復を含有する遺伝子の有害活性の低減のための化合物
Vainshtein et al. Quinazoline-based tricyclic compounds that regulate programmed cell death, induce neuronal differentiation, and are curative in animal models for excitotoxicity and hereditary brain disease
Suh A new era of disease modeling and drug discovery using induced pluripotent stem cells
Wang et al. The relationship of olfactory function and clinical traits in major depressive disorder
Wilson et al. Effects of optogenetic stimulation of basal forebrain parvalbumin neurons on Alzheimer’s disease pathology
Miller et al. Novel inter-hemispheric white matter connectivity in the BTBR mouse model of autism
Kumari et al. U1 snRNA over-expression affects neural oscillations and short-term memory deficits in mice
Khan et al. PDCD6IP, encoding a regulator of the ESCRT complex, is mutated in microcephaly
WO2006091964A8 (en) Regulators of protein misfolding and aggregation and methods of using the same
Jiao et al. TMEM106B aggregation in neurodegenerative diseases: linking genetics to function
CN105246475A (zh) 用于治疗dna修复缺陷障碍的治疗剂和方法
Balendra et al. Quo vadis motor neuron disease?
Renton An update on pain.
AU2018376605B2 (en) A novel method of treating dystonia
US10882821B1 (en) Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
Cuturic Huntington’s Disease